A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 12 Weeks in Adults With Active Primary Sjögren's Syndrome (pSS)
Study sponsor: Lakefront Biotherapeutics NV · LKFT
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2021-10-28Actual
Enrollment · participants31Actual
Source updated2023-09-18Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.